Biocon Board to Consider Biologics Investment via Share Swap

Biocon's Board will consider an investment in subsidiary Biocon Biologics via a share swap arrangement on May 7, 2026.
The investment involves acquiring BBL equity shares by issuing Biocon shares on a preferential private placement basis.
Shareholder approval for the transaction will be sought separately through a Postal Ballot process.
This intimation is made pursuant to SEBI Listing Regulations Regulation 29(1) requirements.